tiprankstipranks
Trending News
More News >

Calliditas Therapeutics downgraded to Hold from Buy at SEB Equities

SEB Equities analyst Christopher Udhe downgraded Calliditas Therapeutics to Hold from Buy with a SEK 208 price target after Asahi Kasei announced an agreement to acquire Calliditas for about $39 per ADS or about $1.1B.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue